However, the use of RITs to deplete Tregs has strong side effects, as this therapy also affects CD4+ CD25hi effector T cells, further weakening the body’s anti-tumor immunity and increasing the patient’s risk of developing autoimmune diseases [25, 27]. Here, CD4 is linked to neoplasm.